^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ofranergene obadenovec (VB-111)

    i
    Other names: VB-111, GT-111, VB 111, VB11, Ofra-Vec
    Company:
    NANO MRNA, VBL Therap
    Drug class:
    Angiogenesis inhibitor, Vascular disrupting agent
    Related drugs:
    24d
    VB-111 in Surgically Accessible Recurrent/Progressive GBM (clinicaltrials.gov)
    P2, N=15, Terminated, Dana-Farber Cancer Institute | Active, not recruiting --> Terminated; Trial stopped at request of VBL Therapeutics, as they are no longer pursuing their VB-111 development program.
    Trial termination
    |
    Avastin (bevacizumab) • ofranergene obadenovec (VB-111)
    6ms
    VB-111 in Surgically Accessible Recurrent/Progressive GBM (clinicaltrials.gov)
    P2, N=15, Active, not recruiting, Dana-Farber Cancer Institute | Trial primary completion date: Mar 2024 --> Aug 2024
    Trial primary completion date
    |
    Avastin (bevacizumab) • ofranergene obadenovec (VB-111)
    8ms
    VB-111 (ofranergene obadenovec) in combination with nivolumab in patients with microsatellite stable colorectal liver metastases: a single center, single arm, phase II trial. (PubMed, J Immunother Cancer)
    In patients with MSS CLM, VB-111 and nivolumab did not improve overall response rate or survival but were tolerated with minimal toxicities. While challenging to distinguish between antiviral or antitumor, correlative studies demonstrated an immune response with activation and proliferation of CD8 T cells systemically that was poorly sustained.
    P2 data • Journal • Combination therapy
    |
    CD8 (cluster of differentiation 8) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10)
    |
    Opdivo (nivolumab) • ofranergene obadenovec (VB-111)
    11ms
    VB-111 in Surgically Accessible Recurrent/Progressive GBM (clinicaltrials.gov)
    P2, N=15, Active, not recruiting, Dana-Farber Cancer Institute | Trial completion date: Jan 2024 --> Jun 2024 | Trial primary completion date: Oct 2023 --> Mar 2024
    Trial completion date • Trial primary completion date
    |
    Avastin (bevacizumab) • ofranergene obadenovec (VB-111)
    1year
    VB-111 in Surgically Accessible Recurrent/Progressive GBM (clinicaltrials.gov)
    P2, N=15, Active, not recruiting, Dana-Farber Cancer Institute | Trial primary completion date: Jun 2023 --> Oct 2023
    Trial primary completion date
    |
    Avastin (bevacizumab) • ofranergene obadenovec (VB-111)
    over1year
    VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov)
    P2, N=14, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed
    Trial completion • Combination therapy • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS wild-type • RAS wild-type
    |
    Opdivo (nivolumab) • ofranergene obadenovec (VB-111)
    2years
    VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov)
    P2, N=13, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting | N=27 --> 13
    Enrollment closed • Enrollment change • Combination therapy
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS wild-type • RAS wild-type
    |
    Opdivo (nivolumab) • ofranergene obadenovec (VB-111)
    over3years
    Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I/II study are associated with an immunotherapeutic effect. (PubMed, Gynecol Oncol)
    Treatment with VB-111 in combination with paclitaxel was safe and well tolerated. Favorable tumor responses and overall survival outcomes were associated with induction of an immunotherapeutic effect.
    P1/2 data • Journal
    |
    CD8 (cluster of differentiation 8)
    |
    paclitaxel • ofranergene obadenovec (VB-111)
    over4years
    [VIRTUAL] Clinical trial in progress: Pivotal study of VB-111 combined with paclitaxel versus paclitaxel for treatment of platinum-resistant ovarian cancer (OVAL, VB-111-701/GOG-3018). (ASCO 2020)
    Enrollment expansion to Europe is planned in 2020. Research Funding: VBL Therapeutics
    Clinical
    |
    CD8 (cluster of differentiation 8)
    |
    paclitaxel • ofranergene obadenovec (VB-111)